p230 does not always predict a mild clinical course in myeloid malignancies: e19a2 bcr/abl fusion transcript with additional chromosome abnormalities in a patient with acute monoblastic leukemia (M5a) [4]

Haematologica

Volumn 86, Issue 3, 2001, Pages 320-321

  Bernasconi, P ^a   Calatroni, S ^a   Boni, M ^a   Cavigliano, P M ^a   Pagnucco, G ^a   Bernasconi, C ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

AML M5a

Indexed keywords

ANTINEOPLASTIC AGENT; CYTARABINE; IDARUBICIN;

ACUTE LEUKEMIA; ACUTE MONOCYTIC LEUKEMIA; ADULT; AGED; CASE REPORT; CHROMOSOME ABERRATION; CLINICAL ARTICLE; CYTOGENETICS; DISEASE COURSE; FEMALE; HUMAN; HUMAN CELL; KARYOTYPE; LETTER; MALE; MYELOPROLIFERATIVE DISORDER; PATIENT MONITORING; PHILADELPHIA 1 CHROMOSOME;

GENES, ABL; HUMANS; KARYOTYPING; LEUKEMIA, MONOCYTIC, ACUTE; LEUKEMIA, MYELOID, PHILADELPHIA-POSITIVE; MALE; MIDDLE AGED; PEPTIDES; RNA, MESSENGER;

EID: 0035070741     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (10)

1. New type of Bcr/Abl junction in Philadelphia chromosome-positive chronic myelogenous leukemia
2. Establishment and molecular characterization of a novel leukemic cell line with Philadelphia chromosome expressing p230 BCR/ABL fusion protein
3. Neutrophilic-chronic myeloid leukemia: A distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction)
4. Elevated platelet count features the variant type of BCR/ABL junction in chronic myelogenous leukaemia
5. A new case of chronic myeloid leukemia with c3/a2 BCR/ABL junction. Is it really a distinct disease?
6. BCR-ABL transcript with an e19a2 (c3a2) junction in classical chronic myeloid leukemia
7. Typical chronic myelogenous leukemia with e19a2 junction BCR/ABL transcript
8. Chronic myeloid leukemia with e19a2 (c3a2) BCR/ABL fusion junction: Is it truly a benign disease?
9. P230 BCR/ABL protein may be associated with an acute leukaemia phenotype
10. Additional translocation (8;21)(q22;q22) in a patient with Philadelphia-positive chronic myelogenous leukaemia in the blastic phase